DK1256339T3 - Transdermalt terapeutisk system for opnåelse af høje plasmaniveauer af rotigotin i behandlingen af Parkinsons sygdom - Google Patents

Transdermalt terapeutisk system for opnåelse af høje plasmaniveauer af rotigotin i behandlingen af Parkinsons sygdom

Info

Publication number
DK1256339T3
DK1256339T3 DK01111109T DK01111109T DK1256339T3 DK 1256339 T3 DK1256339 T3 DK 1256339T3 DK 01111109 T DK01111109 T DK 01111109T DK 01111109 T DK01111109 T DK 01111109T DK 1256339 T3 DK1256339 T3 DK 1256339T3
Authority
DK
Denmark
Prior art keywords
rotigotine
parkinson
therapeutic system
transdermal therapeutic
disease
Prior art date
Application number
DK01111109T
Other languages
Danish (da)
English (en)
Inventor
Thomas Dr Lauterbach
Dietrich Wilhelm Schacht
Hans-Michael Dr Wolff
Walter Dr Mueller
Original Assignee
Sanol Arznei Schwarz Gmbh
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8177356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1256339(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanol Arznei Schwarz Gmbh, Lohmann Therapie Syst Lts filed Critical Sanol Arznei Schwarz Gmbh
Application granted granted Critical
Publication of DK1256339T3 publication Critical patent/DK1256339T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Optical Elements Other Than Lenses (AREA)
  • Radiation-Therapy Devices (AREA)
DK01111109T 2001-05-08 2001-05-08 Transdermalt terapeutisk system for opnåelse af høje plasmaniveauer af rotigotin i behandlingen af Parkinsons sygdom DK1256339T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01111109A EP1256339B1 (fr) 2001-05-08 2001-05-08 Système thérapeutique transdermique pour l'obtention de taux plasmatiques élevés de rotigotine dans le traitement de morbus Parkinson

Publications (1)

Publication Number Publication Date
DK1256339T3 true DK1256339T3 (da) 2004-02-09

Family

ID=8177356

Family Applications (2)

Application Number Title Priority Date Filing Date
DK01111109T DK1256339T3 (da) 2001-05-08 2001-05-08 Transdermalt terapeutisk system for opnåelse af høje plasmaniveauer af rotigotin i behandlingen af Parkinsons sygdom
DK02740569T DK1471892T3 (da) 2001-05-08 2002-05-06 Transdermalt terapeutisk system til parkinsons sygdom, der inducerer höje rotigotinplasmaniveauer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK02740569T DK1471892T3 (da) 2001-05-08 2002-05-06 Transdermalt terapeutisk system til parkinsons sygdom, der inducerer höje rotigotinplasmaniveauer

Country Status (15)

Country Link
EP (3) EP1344522A1 (fr)
JP (2) JP5026656B2 (fr)
KR (1) KR100974974B1 (fr)
CN (2) CN102172351B (fr)
AT (2) ATE251901T1 (fr)
CY (1) CY1109861T1 (fr)
DE (2) DE60100994T2 (fr)
DK (2) DK1256339T3 (fr)
ES (2) ES2204780T3 (fr)
HK (1) HK1049444B (fr)
HU (1) HU229350B1 (fr)
PT (2) PT1256339E (fr)
RU (1) RU2272625C2 (fr)
WO (1) WO2002089778A2 (fr)
ZA (1) ZA200209982B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2203563T3 (es) * 2001-05-08 2004-04-16 Schwarz Pharma Ag Sistema terapeutico transdermico mejorado para el tratamiento de la enfermedad de parkinson.
DE10220230A1 (de) * 2002-05-06 2003-11-27 Sanol Arznei Schwarz Gmbh Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
DE10334188B4 (de) 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10338174A1 (de) 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
DE10359528A1 (de) 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
EP1547592A1 (fr) 2003-12-23 2005-06-29 Schwarz Pharma Ag Formulation intranasale contenant
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE10361259A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
JP2008514376A (ja) * 2004-09-29 2008-05-08 シュウォーツ ファーマ インコーポレイテッド パーキンソン病のための経皮治療システム
CN101147739B (zh) * 2007-07-06 2010-12-08 北京康倍得医药技术开发有限公司 含罗替戈汀的组合物及其制药用途以及含该组合物的透皮贴剂
DE102008060203A1 (de) 2008-12-07 2010-06-10 Dietrich Wilhelm Schacht Wirkstoffstabilisierende flächenförmige Vorrichtung
EP2201941A1 (fr) 2008-12-29 2010-06-30 UCB Pharma GmbH Technologie de fabrication de pavé
WO2011048491A2 (fr) * 2009-10-19 2011-04-28 Actavis Group Ptc Ehf Co-précipités de rotigotine amorphes
EP3257504B1 (fr) 2009-12-22 2024-06-19 UCB Biopharma SRL Polyvinylpyrrolidone pour la stabilisation d'une dispersion solide de forme non cristalline de rotigotine
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
BR112015032929B1 (pt) 2013-07-03 2022-08-23 Lts Lohmann Therapie-Systeme Ag Sistema terapêutico transdérmico com componente eletrônico e métodos de produção de um sistema terapêutico transdérmico
CN106456568B (zh) 2014-05-20 2020-03-27 Lts勒曼治疗系统股份公司 包含界面调节剂的经皮递送系统
JP6895755B2 (ja) 2014-05-20 2021-06-30 エルテーエス ローマン テラピー−ジステーメ アーゲー 経皮送達システムにおける活性薬剤の放出を調節するための方法
JP6573913B2 (ja) 2014-05-20 2019-09-11 エルテーエス ローマン テラピー−ジステーメ アーゲー ロチゴチンを含む経皮送達システム
KR102364378B1 (ko) * 2014-05-21 2022-02-16 에스케이케미칼 주식회사 안정성을 향상시킨 로티고틴 함유 경피흡수제제
DE102014114282A1 (de) 2014-10-01 2016-04-07 Neuraxpharm Arzneimittel Gmbh Transdermales therapeutisches System mit Rotigotin zur Behandlung von Morbus Parkinson
CN110121344A (zh) 2016-12-28 2019-08-13 久光制药株式会社 含布托啡诺的贴附剂
DE102018120505A1 (de) 2017-10-20 2019-04-25 Amw Gmbh Verhinderung der Kristallisation von Wirkstoffen in transdermalen Darreichungssystemen
FI3854388T3 (fi) 2020-01-24 2023-11-27 Luye Pharma Switzerland Ag Transdermaalinen hoitojärjestelmä, jossa on vaikuttava aine rotigotiini ja ainakin yksi ei-amiiniresistentti silikoniliima

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0751515B2 (ja) * 1986-09-10 1995-06-05 明治製菓株式会社 経皮吸収製剤
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5989586A (en) 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19940238A1 (de) * 1999-08-25 2001-03-01 Lohmann Therapie Syst Lts Wirkstoffhaltiges therapeutisches System zur Applikation auf der Haut mit mindestens zwei polymerhaltigen Schichten

Also Published As

Publication number Publication date
DK1471892T3 (da) 2009-12-07
JP2010106037A (ja) 2010-05-13
CN1606435A (zh) 2005-04-13
EP1344522A1 (fr) 2003-09-17
HUP0500525A2 (hu) 2005-09-28
KR20030016373A (ko) 2003-02-26
PT1256339E (pt) 2004-02-27
HK1049444A1 (en) 2003-05-16
CN102172351A (zh) 2011-09-07
RU2003133217A (ru) 2005-04-20
EP1256339B1 (fr) 2003-10-15
EP1256339A1 (fr) 2002-11-13
ES2331787T3 (es) 2010-01-15
ATE251901T1 (de) 2003-11-15
PT1471892E (pt) 2009-12-23
JP5026656B2 (ja) 2012-09-12
ES2204780T3 (es) 2004-05-01
HU229350B1 (en) 2013-11-28
DE60100994T2 (de) 2004-07-22
EP1471892A2 (fr) 2004-11-03
WO2002089778A2 (fr) 2002-11-14
ZA200209982B (en) 2003-03-24
CN102172351B (zh) 2013-07-17
RU2272625C2 (ru) 2006-03-27
JP2004536054A (ja) 2004-12-02
HK1049444B (zh) 2004-03-19
KR100974974B1 (ko) 2010-08-09
CY1109861T1 (el) 2014-09-10
WO2002089778A3 (fr) 2004-08-19
EP1471892B1 (fr) 2009-09-30
DE60100994D1 (de) 2003-11-20
ATE444061T1 (de) 2009-10-15
DE60233898D1 (de) 2009-11-12

Similar Documents

Publication Publication Date Title
DK1256339T3 (da) Transdermalt terapeutisk system for opnåelse af høje plasmaniveauer af rotigotin i behandlingen af Parkinsons sygdom
DK1392256T3 (da) Forbedret transdermalt behandlingssystem til behandling af Parkinsons sygdom
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
DE60121301D1 (de) Flibanserin zur Behandlung extrapyramidaler Bewegungsstörungen
ATE493981T1 (de) Einmal tägliche dosierformen von trospium
HUP0102728A2 (hu) Módszerek és transzdermális készítmények fájdalom csillapítására
PT1383752E (pt) 3-piperidinopropiofenonas deuteradas assim como farmacos contendo estes compostos
DE50005529D1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
DE60211139D1 (de) Feste arzneizusammensetzung enthaltend 4'-cyano-trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy-2-methylpropiono- m toluidide und pvp
ATE262893T1 (de) Darreichungsformen zur behandlung von oralen mykosen
GEP201606538B (en) Preoperative treatment of post operative pain
SE0102887D0 (sv) New formulation
HK1065305A1 (en) Substituted 4-aminocyclohexanol derivatives
TR200301916T4 (tr) Rotigotinin yüksek plazma seviyelerini kapsayan parkinson hastalığına yönelik transdermal terapötik sistem.